Company
Synergy of tradition and modernity for innovative products
Fette Pharma GmbH aims to offer medical cannabis in Germany for the promising treatment and care of patients as well as in the form of a practice-oriented selection of individually tailored therapy options.
With the Israeli company Cannbit, Fette Pharma has a partner at its side that is playing a pioneering role in the era of modern medical cannabis. This collaboration gave rise to the RE:CANNIS brand.
RE:CANNIS – The new standard in medical cannabis therapy
Known for thousands of years as a plant with healing properties, medicinal cannabis today plays an important role in the adjuvant therapy of various diseases. Fortunately, clinical research has picked up speed in recent years. Israel is at the forefront of both clinical research and application. Many groundbreaking studies there are based on products and cannabis genetics from our partner Cannbit.
More than 16 years of experience in medical cannabis research
Thanks to the cooperation between Fette Pharma and Cannbit, it is possible to utilize the more than 16-year research lead of the Israeli partner company Cannbit in Germany as well. The RE:CANNIS preparations are based on valid clinical study data and therapeutic experience with more than 40,000 patients, which are documented in scientific publications, and represent their genetic advancements.
More than 35 clinical and preclinical studies, more than 20 publications in leading scientific media
RE:CANNIS products are based on extensive therapeutic experience that has demonstrated their efficacy in various indications in numerous clinical and preclinical studies as well as in scientific publications.
The successes of medical cannabis therapy documented in studies include indications such as chronic pain syndrome, fibromyalgia, oncological diseases, Crohn's disease, ulcerative colitis, dementia, Parkinson's disease, Tourette's syndrome, epilepsy and autism spectrum disorders.
More than 40,000 patient data for the further development of therapy options
Advances in research, decades of therapeutic experience and more than 40,000 patient data now enable highly targeted therapy with cannabinoids and cannabis genetics that have already been successfully used in Germany.
